Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 1/20 | 0.47 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.44 |
| ▸ | PPARA | Q07869 | 1/20 | 0.40 |
| ▸ | TAAR1 | Q96RJ0 | 7/20 | 0.40 |
| ▸ | HTR2A | P28223 | 1/20 | 0.38 |
| ▸ | MAOB | P27338 | 2/20 | 0.37 |
| ▸ | CA12 | O43570 | 1/20 | 0.37 |
| ▸ | CA1 | P00915 | 1/20 | 0.37 |
| ▸ | CA2 | P00918 | 1/20 | 0.37 |
| ▸ | CA7 | P43166 | 1/20 | 0.37 |
| ▸ | CA9 | Q16790 | 1/20 | 0.37 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.37 |
| ▸ | PDCD1 | Q15116 | 1/20 | 0.36 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.36 |
| ▸ | BACE1 | P56817 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Biphenyl SCHEMBL30337 | 0.82 | TAAR1 (0.52) | DPP4ADRA2CTAAR1HTR2A | |
| SCHEMBL607543 | 0.82 | DPP4 (0.56) | DPP4PPARACA12CA1CA2 | |
| SCHEMBL1868872 | 0.82 | DPP4 (0.68) | DPP4ADRA2CTAAR1HTR2AMAOB | |
| Biphenyl SCHEMBL19410947 | 0.80 | TAAR1 (0.50) | DPP4ADRA2CTAAR1HTR2A | |
| Hydrochloric Acid SCHEMBL30641921 | 0.80 | DPP4 (0.54) | DPP4PPARACA12CA1CA2 | |
| SCHEMBL10798302 | 0.78 | DPP4 (0.52) | DPP4PPARACA12CA1CA2 | |
| SCHEMBL29687091 | 0.78 | TAAR1 (0.56) | ADRA2CTAAR1HTR2A | |
| SCHEMBL2773498 | 0.78 | TAAR1 (0.56) | ADRA2CTAAR1HTR2A | |
| Cyanide SCHEMBL28342474 | 0.77 | DPP4 (0.50) | DPP4ADRA2CPPARACA12CA1 | |
| SCHEMBL27806648 | 0.77 | PPARA (0.50) | DPP4PPARACA12CA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10894784-B2 | Heteroarylbenzimidazole compounds | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2021-01-19 | — | — | US | disclosed |
| US-20190047980-A1 | HETEROARYLBENZIMIDAZOLE COMPOUNDS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2019-02-14 | — | — | US | disclosed |
| US-9670202-B2 | Substituted triazolopyridines | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2017-06-06 | — | — | US | disclosed |
| US-20160297811-A1 | SUBSTITUTED TRIAZOLOPYRIDINES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2016-10-13 | — | — | US | disclosed |
| US-20140120087-A1 | TRIAZOLOPYRIDINES | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2014-05-01 | — | — | US | disclosed |
| US-20130121994-A1 | TRIAZOLOPYRIDINE DERIVATIVES | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2013-05-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140120087-A1 | TRIAZOLOPYRIDINES | QDPR, TBXA2R, KCNJ11 | DPP4 580/4885ADRA2C 22/4885PPARA 2731/4885 |
| US-20190047980-A1 | HETEROARYLBENZIMIDAZOLE COMPOUNDS | CCNI, CCNT2, CDK2 | DPP4 3430/4885ADRA2C 1607/4885PPARA 1140/4885 |
| US-10894784-B2 | Heteroarylbenzimidazole compounds | CCNI, CCNT2, CDK2 | DPP4 3430/4885ADRA2C 1607/4885PPARA 1140/4885 |
| US-20130121994-A1 | TRIAZOLOPYRIDINE DERIVATIVES | TTBK1, BUB1, TTK | DPP4 3464/4885ADRA2C 1388/4885PPARA 4069/4885 |
| US-20160297811-A1 | SUBSTITUTED TRIAZOLOPYRIDINES | QDPR, TBXA2R, KCNJ11 | DPP4 496/4885ADRA2C 11/4885PPARA 2413/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.